Overall verdict
Neutral
4.5/10
1-year performance
+16.93%
Score breakdown
Up 16.9% over 1 year, 84% of the 52-week range.
Strongest: Valuation 7.0/10. Weakest: Growth 0.0/10.
28 analysts, target +0.0% vs the price.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand ; migraine products under the Nurtec ODT/Vydura and Zavzpret brand ;
vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands ; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity ; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands ;
and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands.
Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Nyse
United States
CEO
Dr. Albert Bourla D.V.M., Ph.D.
Founded
1849
Employees
75 000
Revenue / employee
834 387 USD
Next earnings
November 3, 2026 (Q3 2026)
Institutional holders
- BlackRock, Inc.9.33%
- VANGUARD CAPITAL MANAGEMENT LLC6.56%
- STATE STREET CORP5.41%
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM3.84%
- GEODE CAPITAL MANAGEMENT, LLC2.38%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.10%
- Fisher Asset Management, LLC1.92%
- MORGAN STANLEY1.70%
- NORGES BANK1.08%
- Other institutions36.57%
- Rest of the register29.10%
2824 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
29.21 USD
52-week low
23.58 USD
1-year performance
16.93%
Rising
Year-to-date performance
12.81%
Rising
Drawdown
-3.12%
Near its high
Position in the 52-week range
84% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned less, while shaking 1.7 times harder.
10,000 € placed at the end of September 2009 are worth today
| Pfizer | 46 442 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 1.7 times as much as the world ETF.
- Worst fall:-59 % between December 2021 and April 2025. 10,000 € placed at the top fell to 4 117 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Pfizer earned less than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Pfizer: 46 442 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 17.40 USD - 68.65 USD (comparables only)
The price implies growth of 0.89% per year; the company grows at -3.57%.
Gross margin 64.8%, net margin 6.8%, ROIC 3.0%, ROE 5.0%.
Net margin
6.81%
Fair
Sector 9.52%|S&P 12.97%
Gross margin
64.83%
High
Return on equity (ROE)
4.99%
Fair
Sector 6.17%|S&P 16.52%
Return on invested capital (ROIC)
2.97%
Low
Free cash flow margin (FCF)
17.25%
Exceptional
Profit-to-cash conversion (FCF conversion)
2.53x
Exceptional
Margin stability
10.2 pts
Very uneven
Revenue to net income
Growth
0.0/10Revenue up 2.6% over 1 year, 8.5% a year over 5, EPS -3.6% a year over 5.
Revenue (trailing 12 months)
63.7Md USD
Revenue growth (1y)
2.60%
Moderate
Revenue growth (3y)
-37.63%
Declining
EPS growth (1y)
-108.60%
Declining
EPS CAGR (5y)
-3.57%
Declining
EPS revisions (3 months)
0.55%
Revised up
Valuation
7.0/10P/E 37.5x, forward P/E 17.8x, EV/EBITDA 7.0x. The multiple sits in the 75th percentile of its own 5-year history.
P/E (TTM)
37.5x
Expensive
Sector 27.3x|S&P 23.0x
Forward P/E
17.8x
Fair
EV / EBITDA
7.0x
Cheap
Sector 16.1x|S&P 14.5x
PEG
—
Sector 1.05|S&P 0.86
Fair value (reverse DCF)
43.03 USD
Deeply undervalued
P/E vs its own 5-year history
among the 25% highest valuations
Pricier than usual
Market cap
161Md USD
Financial strength
5.9/10Cash covers 18.5% of the debt, net debt/EBITDA 2.3x.
Net debt / EBITDA
2.3x
Tight
Gearing (net debt / equity)
60.23%
Tight
Cash
11.7Md USD
Cash / market cap
7.28%
Tight
Cash / total debt
18.51%
Tight
Net debt
51.5Md USD
Equity
85.5Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 28.41 USD
- MM2028.02
- MM5026.91
- MM20026.32
- RSI 1463.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.11%
200-day average slope, 3 months
+1.74%
50-day average slope, 1 month
+5.77%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
0.94 % per day
Volatility change
-26.52%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 1.59 (9) | 2.98 (25) | 62 235 (25) | 24 303 (12) | 8 900 (9) |
| 2027 | 2.05 (9) | 2.90 (25) | 59 766 (24) | 24 139 (11) | 11 080 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 15, 2026.
Same sub-industry: 509 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BMY | 7.2 | 7.8 | 125Md USD | 13.5x | 18.9 % | 5.8 % | 14.3 % | 1.9x | 9.2 % | 37.4 % | ||
| 2 | LLY | 6.7 | 6.0 | 1.1T USD | 39.1x | 33.5 % | 47.7 % | 39.8 % | 1.2x | 1.7 % | 58.4 % | ||
| 3 | NOVO B | 6.6 | 7.4 | 170Md USD | 9.5x | 35.3 % | 2.1 % | 38.9 % | 0.7x | 6.7 % | -32.6 % | ||
| 4 | NOVN | 6.4 | 6.4 | 261Md USD | 22.6x | 23.3 % | -2.0 % | 17.2 % | 1.0x | 6.3 % | 22.0 % | ||
| 5 | JNJ | 6.3 | 5.9 | 649Md USD | 31.2x | 21.5 % | 6.6 % | 17.5 % | 0.9x | 3.4 % | 53.7 % | ||
| 6 | ROP | 6.1 | 5.7 | 352Md USD | 23.7x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 5.2 % | 35.9 % | ||
| 7 | AZN | 5.8 | 6.5 | 255Md USD | 24.8x | 17.0 % | 5.8 % | 14.3 % | 1.2x | 4.2 % | 10.7 % | ||
| 8 | MRK | 5.0 | 4.4 | 365Md USD | 118.4x | 4.8 % | 4.9 % | 3.6 % | 1.2x | 4.4 % | 85.2 % | ||
| 9 | PFE | 4.5 | 4.5 | 161Md USD | 37.5x | 6.8 % | 2.6 % | 3.0 % | 2.3x | 6.8 % | 16.9 % |
